MONDAY 30 JUNE 14.30 – 17.00

Oxford Technology Management Presentations

Presentations by local technology companies seeking funding from business angels

14.30

Introduction by Chair

Lucius Cary OBE, Founder and Managing Director, Oxford Technology Management Ltd

14.45

Glide Pharma

Funding sought: £2m

Glide Pharma is developing a needle-free drug delivery technology and hopes to be in man for the first time in August 2008. In 2007 Glide won the prestigious Medical Futures award. Glide is now seeking up to £2m to fund its continuing development.

15.00

Diamond Hard Surfaces Ltd

Funding sought: £375k

Diamond Hard Surfaces Ltd has developed a process to coat objects in thick amorphous DLC. The coating exhibits extreme material properties of diamond, such as ultra-high hardness, ultra low coefficient of friction and the ability to withstand large surface loads. UK and PCT patents have been applied for. The company’s material combines the advantages of DLC in a thick film creating a new market sector competing both with thin and thick coatings with distinct technical advantages. The company recently received its first commercial order and is now seeking to raise £375k to build a UK production facility.

15.15

Dexela

Funding sought: £2.5m

Dexela is seeking up to £2.5m, of which £2m is already committed. It is developing technology for low dose 3D mammography, known as tomosynthesis. Dexela has developed a leading technology and intellectual property portfolio in tomosynthesis image acquisition, reconstruction and review. Its initial focus is on breast imaging, but its technology also has applications in other types of 3D medical imaging, as well as security and industrial applications. Dexela has licensed software to GE and XCounter and discussions are underway with key players in the industry concerning partnerships. Dexela was awarded a £350k grant by the DTI in 2007.

15.30

Scancell

Funding sought: £1.5m

Scancell is developing a pipeline of DNA cancer vaccines based on its patented ImmunoBodyTM platform which overcomes the significant limitations of existing approaches. With outstanding ‘proof of concept’ in vivo data in place and collaborations with major pharmaceutical companies in negotiation, new funding of at least £1.5m is now sought. Existing shareholders will be supporting this round which will enable the lead melanoma vaccine to enter the clinic. Concurrent with the funding, Scancell will seek a listing on the Plus market. A positive outcome would have a major impact on value and position the company for possible exit.

15.45

Prosurgics

Funding sought: £4m

Prosurgics designs and manufactures surgical robots. The company is expanding rapidly and it is currently launching the latest robot in its range: the Freehand, a camera holding robot for laparascopic surgery. Prosurgics’ robotic product range addresses EU and US surgical markets of a value well in excess of $1bn per year and a high proportion of this comes from recurring revenues arising from the sale of disposables attached to each robotic arm. Prosurgics has already raised £4m in 2008, and is seeking up to £4m of additional capital to fund its expansion. Shares are offered at £1.43 per share at a pre-funding valuation of £8m and EIS tax relief is available.

16.00

Naked Objects Group

Funding sought: £300k

Naked Objects has achieved a major success with its first software installation for the DSFA (Department for Social & Family Affairs) in Ireland where the software is in active use by 1000 staff administering €5bn in pensions and other social benefit payments per annum. The company expects to achieve the first sales of its new product, running on the Microsoft .NET platform. £300k is sought to finance this expansion of which £100k is likely to come from OT4.

16.15

Inscentinel

Funding sought: £75k

Inscentinel is making good progress developing its range of sensors based on the exquisitely sensitive olfactory sense of bees. VASOR, the first field-deployable instrument based on this technology and able to sense five substances, should be available for trials by summer 2008. Inscentinel is seeking £75k for 14% of the equity for working capital. Most of this is already committed by existing shareholders.

Organised by Oxford Technology Management

(Return to Programme at a Glance)

Financial Services and Markets Act 2000
The fund raising sessions at Venturefest provide an opportunity for investors to meet entrepreneurs and companies seeking investment and enables investors to receive information on investment opportunities of interest to them. The Networks do not advise on the merits or risks of specific investment proposals. The responsibility for the decision on specific investment lies with the parties concerned.